Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - AdaptVac

Drug Profile

Coronavirus vaccine - AdaptVac

Alternative Names: COVID-19 vaccine - AdaptVac

Latest Information Update: 10 May 2020

At a glance

  • Originator AdaptVac
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 06 May 2020 Corona virus vaccine licensed to Bavarian Nordic
  • 12 Mar 2020 Coronavirus vaccine - AdaptVac is available for licensing as of 12 Mar 2020. https://www.adaptvac.com/
  • 09 Mar 2020 Early research in COVID-2019 infections (Prevention) in Denmark (Parenteral)

Development Overview

Introduction

A coronavirus vaccine (COVID 19) is being developed by AdaptVac (joint-venture between ExpreS2ion Biotechnologies and NextGen Vaccines, a spin-out of the University of Copenhagen) for prevention against COVID-2019 infections caused by the SARS-CoV-2 virus. The company is using its universal viral Capsid-Like Particle (CLP) technology to develop the COVID 19 candidate. The protein based CLP approach, activates the immune system in a potentially synergistic manner. Early research is underway in Denmark.

AdaptVac's viral capsid-like particle technology enables quick adaptation of the vaccine to viral mutations. The company utilises the split-protein conjugation system to generate stable isopeptide bound antigen-virus -like particle (VLP) complexes by simply mixing of the antigen and VLP components.

AdaptVac is actively seeking partners for the development of the coronavirus vaccine (AdaptVac pipeline, March 2020).

AdaptVac is a joint venture between ExpreS2 ion Biotechnologies and NextGen Vaccines, combining ExpreS2 ion’s platform with novel proprietary and ground-breaking viral capsid-like particle (CLP) technology developed at the University of Copenhagen.

Company Agreements

In May 2020, Bavarian Nordic entered into an exclusive agreement with AdaptVac to license AdaptVac’s proprietary capsid virus like particle (VLP) based SARS-CoV-2 subunit vaccine. Both the parties seek to enter into the final license agreement within the next two months. Upon execution of a final license agreement, Bavarian Nordic will make an initial upfront payment to Adaptvac in addition to future development and sales milestones and royalties. [1]

In April 2020, AdaptVac and AGC Biologics entered into the manufacturing agreement for manufacture and scale-up of the COVID-19 (SARS-CoV-2) coronavirus vaccine. This agreement leverages AGC Biologics global manufacture expertise to accelerate the development and GMP manufacture of the SARS-CoV-2 capsid-Virus Like Particle (cVLP) vaccine.
[2]

Key Development Milestones

Financing information

In March 2020, AdaptVac received an Horizon 2020 EU grant of €2.7million as part of the PREVENT-nCoV consortium. The company intends to use the funds for development of the coronavirus vaccine as well as to support production of the needed clinical supply of viral capsid-like particles for clinical projects, including AV 001 [see Adis Insight Drug Profile800052950] [3] [4] .

Patent Information

In January 2020, AdaptVac was granted a US patent number 10 526 376 B2 “Virus-like particle with efficient epitope display" covering its viral capsid-like particle (CLP) technology platform, and any vaccine produced using it (including the Her2 immunotherapy, AV 001 [see Adis Insight Drug Profile 800052950]. The new patent expands AdaptVac’s protection, thereby covering the entire pipeline of vaccines and immunotherapies including the heart disease therapy, targeting cholesterol reduction, as well as a long list of viral, bacterial, and additional chronic disease vaccines. The patent is valid until 2036 [5] .

The University Of Copenhagen has pending patent applications CA 3 010 975 A1, EP 3 244 915 A1, EA 201 791 598 A8, WO 2016 112 921 A1 and AU 2016 207 099 A1, DE 16 703 049 T1 entitled "Virus like particle with efficient epitope display", covering its virus-like particle (VLP) based vaccine. The patent relates to a technology and method for making a virus-like particle based vaccine with efficient epitope display and capable of inducing a strong and long-term protective immune response. The patent is related to the use of VLP-based vaccine for the prophylaxis and/or treatment of a diseases including, but not limited to, cancer, cardiovascular, infectious, chronic, neurological, asthma, allergy, immune-inflammatory diseases or disorders [6] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Viral vaccines, Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E9 (All other viral vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research Denmark Parenteral / unspecified AdaptVac 09 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
AdaptVac Originator Denmark
AdaptVac Owner Denmark
Bavarian Nordic Licensee Denmark
University of Copenhagen Technology Provider Denmark
ExpreS2ion Biotechnologies Technology Provider Denmark
European Commission Funder Belgium
Leiden University Medical Center Collaborator Netherlands
University of Tubingen Collaborator Germany
Wageningen University Collaborator Netherlands

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
AdaptVac - Unspecified - 12 Mar 2020

Future Events

Expected Date Event Type Description Updated
09 Mar 2021 Trial Update AdaptVaC plans a phase I/IIa trial for COVID-2019 infections (Prevention) (Parenteral) by March 2021 (700319708) [4] 15 Mar 2020

Development History

Event Date Update Type Comment
06 May 2020 Licensing Status Corona virus vaccine licensed to Bavarian Nordic [1] Updated 10 May 2020
12 Mar 2020 Licensing Status Coronavirus vaccine - AdaptVac is available for licensing as of 12 Mar 2020. https://www.adaptvac.com/ Updated 15 Mar 2020
09 Mar 2020 Phase Change Early research in COVID-2019 infections (Prevention) in Denmark (Parenteral) [3] Updated 15 Mar 2020
09 Mar 2020 Trial Update AdaptVaC plans a phase I/IIa trial for COVID-2019 infections (Prevention) (Parenteral) by March 2021 [4] Updated 15 Mar 2020
07 Jan 2020 Patent Information AdaptVac has patent protection for viral capsid-like particle (CLP) technology platform and vaccines based on it in USA [5] Updated 15 Mar 2020
15 Jan 2015 Patent Information University Of Copenhagen has patents pending for virus like particle-based vaccine in Canada, Europe, Australia, Germany, Russia and World [6] Updated 15 Mar 2020

References

  1. Bavarian Nordic Enters Agreement with AdaptVac to Advance COVID-19 Vaccine Program.

    Media Release
  2. Manufacturing agreement with AGC Biologics accelerates COVID-19 vaccine program.

    Media Release
  3. AdaptVac's ground-breaking technology central to new EUR2.7M EU grant funded COVID-19 vaccine effort.

    Media Release
  4. PREVENT-nCoV consortium announces EU grant award for COVID-19 vaccine development programme.

    Media Release
  5. Granting of AdaptVac's core platform technology patent in the United States.

    Media Release
  6. Virus-like particle with efficient epitope display. Internet-Doc 2020;.

    Available from: URL: https://patents.google.com/patent/WO2016112921A1/en?oq=DE16703049T1
Back to top